Cortexin vs Semax
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: Broad neuroprotection contexts within Russian clinical practice vs. Stroke recovery or BDNF-mediated neuroprotection research requiring a defined molecule with multicen.
Quick Answers
Which is better, Cortexin or Semax?
Neither compound has a universal evidence advantage. Research distinction: Broad neuroprotection contexts within Russian clinical practice vs. Stroke recovery or BDNF-mediated neuroprotection research requiring a defined molecule with multicen.
What is the key difference between Cortexin and Semax?
Semax is a defined synthetic peptide with reproducible pharmacology; cortexin is a bovine brain extract whose active components are uncharacterized - the gap in molecular definition is the critical distinction.
Evidence Comparison
Semax: multicenter RCT in ischemic stroke (Lebedeva 2008, n=60), defined ACTH(4-7) analog with BDNF mechanism, approved in Russia. Cortexin: Russian clinical data but no multicenter RCT meeting Western design standards. Semax has meaningfully stronger evidence.
Evidence Context Favoring Cortexin
Broad neuroprotection contexts within Russian clinical practice.
Evidence Context Favoring Semax
Stroke recovery or BDNF-mediated neuroprotection research requiring a defined molecule with multicenter trial data.
Side-by-Side Snapshot
| Evidence grade | Cortexin: Level C Semax: Level C |
|---|---|
| Research status | Cortexin: Approved Outside US Semax: Approved Outside US |
| Primary category | Cortexin: Cognitive & Nootropic Semax: Cognitive & Nootropic |
| Cited studies | Cortexin: 2 Semax: 2 |